OraSure Technologies (NASDAQ:OSUR) Director Buys $74,750.00 in Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director Steven Kyle Boyd bought 25,000 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was acquired at an average cost of $2.99 per share, with a total value of $74,750.00. Following the completion of the purchase, the director owned 113,462 shares of the company’s stock, valued at approximately $339,251.38. This trade represents a 28.26% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Steven Kyle Boyd also recently made the following trade(s):

• On Tuesday, May 12th, Steven Kyle Boyd bought 25,000 shares of OraSure Technologies stock. The stock was acquired at an average cost of $2.98 per share, with a total value of $74,500.00.

OraSure Technologies Trading Up 1.7%

NASDAQ:OSUR opened at $3.00 on Friday. OraSure Technologies, Inc. has a 1 year low of $2.08 and a 1 year high of $3.82. The stock has a market cap of $206.55 million, a price-to-earnings ratio of -2.88 and a beta of 0.89. The stock has a 50-day moving average price of $3.06 and a two-hundred day moving average price of $2.76.

OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). OraSure Technologies had a negative net margin of 66.42% and a negative return on equity of 18.57%. The business had revenue of $26.76 million during the quarter, compared to analyst estimates of $26.44 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $3.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Altai Capital Management L.P. grew its stake in OraSure Technologies by 73.4% in the third quarter. Altai Capital Management L.P. now owns 3,748,836 shares of the medical instruments supplier’s stock valued at $12,034,000 after purchasing an additional 1,586,488 shares in the last quarter. Peapod Lane Capital LLC grew its stake in OraSure Technologies by 51.1% in the fourth quarter. Peapod Lane Capital LLC now owns 1,018,470 shares of the medical instruments supplier’s stock valued at $2,465,000 after purchasing an additional 344,437 shares in the last quarter. Tudor Investment Corp ET AL bought a new position in OraSure Technologies in the third quarter valued at approximately $808,000. Cannell Capital LLC grew its stake in OraSure Technologies by 12.6% in the third quarter. Cannell Capital LLC now owns 2,099,815 shares of the medical instruments supplier’s stock valued at $6,740,000 after purchasing an additional 234,826 shares in the last quarter. Finally, Odyssean LLC bought a new position in OraSure Technologies in the fourth quarter valued at approximately $162,000. 93.50% of the stock is owned by institutional investors and hedge funds.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.